

RESEARCH ARTICLE

Assessment of dispersion of airborne particles of oral/nasal fluid by high flow nasal cannula therapy

M. C. Jermy^{1*}, C. J. T. Spence², R. Kirton², J. F. O'Donnell^{2,3}, N. Kabaliuk¹, S. Gaw⁴, H. Hockey⁵, Y. Jiang⁶, Z. Zulkhairi Abidin¹, R. L. Dougherty⁷, P. Rowe^{1,2}, A. S. Mahaliyana⁴, A. Gibbs⁴, S. A. Roberts⁸

1 Department of Mechanical Engineering, University of Canterbury, Christchurch, New Zealand, **2** Fisher and Paykel Healthcare, Auckland, New Zealand, **3** School of Nursing College of Health, Massey University, Auckland, New Zealand, **4** School of Physical and Chemical Sciences, University of Canterbury, Christchurch, New Zealand, **5** Biometric Matters Ltd, Hamilton, New Zealand, **6** Department of Statistics, University of Auckland, Auckland, New Zealand, **7** Department of Mechanical Engineering, University of Kansas, Lawrence, United States of America, **8** Department of Microbiology Lab Plus, Auckland District Health Board, Auckland, New Zealand

* mark.jermy@canterbury.ac.nz



OPEN ACCESS

Citation: Jermy MC, Spence CJT, Kirton R, O'Donnell JF, Kabaliuk N, Gaw S, et al. (2021) Assessment of dispersion of airborne particles of oral/nasal fluid by high flow nasal cannula therapy. PLoS ONE 16(2): e0246123. <https://doi.org/10.1371/journal.pone.0246123>

Editor: Sreekumar Othumpangat, Center for Disease control and Prevention, UNITED STATES

Received: May 27, 2020

Accepted: January 13, 2021

Published: February 12, 2021

Copyright: © 2021 Jermy et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting information](#) files.

Funding: This study was partially funded by Fisher & Paykel Healthcare Ltd, who also provided the NHF cannulae (Optiflow) and the NHF source (Airvo/Airvo2). The funder provided support in the form of salaries for authors CJS, JFO, RK and PR, but did not take part in the data collection or reduction. None of the data obtained was excluded from the manuscript. The specific roles of these

Abstract

Background

Nasal High Flow (NHF) therapy delivers flows of heated humidified gases up to 60 LPM (litres per minute) via a nasal cannula. Particles of oral/nasal fluid released by patients undergoing NHF therapy may pose a cross-infection risk, which is a potential concern for treating COVID-19 patients.

Methods

Liquid particles within the exhaled breath of healthy participants were measured with two protocols: (1) high speed camera imaging and counting exhaled particles under high magnification (6 participants) and (2) measuring the deposition of a chemical marker (riboflavin-5-monophosphate) at a distance of 100 and 500 mm on filter papers through which air was drawn (10 participants). The filter papers were assayed with HPLC. Breathing conditions tested included quiet (resting) breathing and vigorous breathing (which here means nasal snorting, voluntary coughing and voluntary sneezing). Unsupported (natural) breathing and NHF at 30 and 60 LPM were compared.

Results

1. Imaging: During quiet breathing, no particles were recorded with unsupported breathing or 30 LPM NHF (detection limit for single particles 33 µm). Particles were detected from 2 of 6 participants at 60 LPM quiet breathing at approximately 10% of the rate caused by unsupported vigorous breathing. Unsupported vigorous breathing released the greatest numbers of particles. Vigorous breathing with NHF at 60 LPM, released half the number of particles compared to vigorous breathing without NHF.

authors are articulated in the 'author contributions' section. YJ and HH carried out statistical analyses under consulting service agreements with Fisher & Paykel Healthcare Ltd; ZZA was supported by a scholarship from the Malaysian Ministry of Higher Education; RD was on sabbatical from the University of Kansas and was partly supported by a University of Canterbury Erskine Fellowship.

Competing interests: Authors CJS, JFO, RK and PR are employees of the funder, Fisher and Paykel Healthcare. The specific roles of these authors are articulated in the 'author contributions' section. YJ and HH carried out statistical analyses under consulting service agreements with Fisher & Paykel Healthcare Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials." I am not aware that the work described in the manuscript has had any impact on product development or marketing, and I am not aware of any affiliation between any of the authors and any manufacturers competing with the funder.

2. Chemical marker tests: No oral/nasal fluid was detected in quiet breathing without NHF (detection limit $0.28 \mu\text{L}/\text{m}^3$). In quiet breathing with NHF at 60 LPM, small quantities were detected in 4 out of 29 quiet breathing tests, not exceeding $17 \mu\text{L}/\text{m}^3$. Vigorous breathing released 200–1000 times more fluid than the quiet breathing with NHF. The quantities detected in vigorous breathing were similar whether using NHF or not.

Conclusion

During quiet breathing, 60 LPM NHF therapy may cause oral/nasal fluid to be released as particles, at levels of tens of μL per cubic metre of air. Vigorous breathing (snort, cough or sneeze) releases 200 to 1000 times more oral/nasal fluid than quiet breathing ($p < 0.001$ with both imaging and chemical marker methods). During vigorous breathing, 60 LPM NHF therapy caused no statistically significant difference in the quantity of oral/nasal fluid released compared to unsupported breathing. NHF use does not increase the risk of dispersing infectious aerosols above the risk of unsupported vigorous breathing. Standard infection prevention and control measures should apply when dealing with a patient who has an acute respiratory infection, independent of which, if any, respiratory support is being used.

Clinical trial registration

ACTRN12614000924651

Introduction

Nasal high flow (NHF) has been increasingly used as an intervention for type 1 respiratory failure. Appropriate use of NHF has been shown to reduce intubation rates, which carries a risk of infection transmission for both patients [1, 2], and healthcare workers [3].

Concerns have been raised about a potential risk of NHF spreading infection by generating aerosols and droplets when used to support patients with acute respiratory infections. NHF therapy is classed by some countries as an aerosol generating procedure (AGP). A systematic review of AGP and risk of transmission of acute respiratory infections (ARI) to healthcare workers (HCW) reported that more invasive respiratory procedures such as tracheal intubation, tracheotomy and manual ventilation were a significant risk factors for SARS transmission [3]. This was based on a single cohort study during the SARS outbreak in Canada in 2003, which was before NHF was in clinical use [4]. In this study, lack of adherence to infection prevention and control practices was identified as a major contributor for HCW acquisition of SARS. The risk of transmission of ARI associated with AGP is very topical with the current COVID-19 pandemic. Clinicians must choose which respiratory therapies they apply, taking into consideration patient acuity, reduction of escalation, and minimization of virus transmission to healthcare workers.

Some countries or healthcare systems have guidance against using NHF for patients with COVID-19 infection, while others are using NHF as a first line therapy. Interestingly, there does not appear any substantive evidence of NHF causing large dispersions of infectious aerosols and infecting healthcare workers. In fact, the low number of relevant dispersion studies

and lack of understanding of infection transmission has been highlighted in three recent publications [5–7].

This paper compares the release of particles of oral/nasal fluids during quiet resting breathing, snorting, voluntary coughing and voluntary sneezing, both in the absence of respiratory therapy and when receiving NHF at 30 and 60 LPM (litres per minute). Two techniques are used to determine volumes of oral/nasal fluid released: high speed optical video microscopy and air sampling with a chemical marker instilled into the nose and mouth. It is our hope that this data will inform evidence-based decisions about using NHF, particularly for patients with ARI.

Methods

Ethical approval was obtained from the Upper South B Regional Ethics Committee, Ministry of Health, New Zealand URB/09/12/064 and the University of Canterbury Human Ethics Committee (refs. 2009/173 and HEC 2017/105). Written, informed consent was obtained from all subjects.

Definitions

In the terminology commonly accepted in healthcare, aerosols are suspensions of small particles, including droplet nuclei, with an aerodynamic diameter of 10 μm or less. Droplets are particles with an aerodynamic diameter of $> 10 \mu\text{m}$. Airborne transmission in a healthcare setting refers to transmission by aerosols of $< 10 \mu\text{m}$ [8]. Particles in either size class can be inhaled, causing virus transfer, depending on proximity and air currents.

(1) Imaging method. Six healthy volunteers participated: three females aged 20 to 27 years, and three males aged 26 to 59 years. Participants wore a medium size Optiflow™ (OPT544, Fisher & Paykel Healthcare, Auckland, New Zealand) NHF cannula. Air flows conditioned to 37°C and 100% relative humidity (44mg/L) were generated with an AIRVO™ 2 humidifier-flow generator (Fisher & Paykel Healthcare). Participants were instructed to breathe with their mouth closed to create higher nasal velocities more likely to release particles. All participants spent at least five minutes acclimatizing to NHF at 30 LPM. Prior to each measurement, 1 mL of 0.9% NaCl solution was instilled into each nostril to artificially moisten the nasal mucosa, as the healthy volunteers do not have the increased mucus production common to viral respiratory infections. Saline has a lower viscosity than nasal mucus. Exposed to the same forces, a lower viscosity fluid will yield a greater mass of droplets [9]. The lower viscosity and greater liquid film thickness achieved by adding saline is therefore a worst-case scenario. 1 ml was assumed sufficient as excess ran out of the nose.

Participants sat with their chin and forehead on a rest. A region of approximately 40 × 30 mm directly below the participants' nostrils was imaged with a high-speed camera (Motion Pro X3™, 1040 frames per second, shutter speed of 40 μs and resolution 1280×1024 pixels, Redlake Imaging Corp.). The region was backlit such that particles and the outline of the nose cast a shadow onto the camera (Fig 1). The left and right nostrils were imaged separately because the camera's depth of field (20mm) could encompass only one nostril entirely.

Videos were analyzed using a Java-based image processing program (Image J, National Institutes of Health, Bethesda, MD, USA) for particle frequency, diameter and velocity. The number of particles were recorded in bins with diameter of 0–50, 50–100, 100–150, 200–500, 500–1000, 1000–2000 and 2000–5000 μm . The smallest detectable particle occupies one pixel i.e. has a diameter of 33.0 μm .

The six experimental conditions, each conducted in triplicate on each nostril, were:

- Quiet breathing (at rest) with no therapy, with 30LPM NHF, and with 60LPM NHF.




Fig 1. Imaging layout.

<https://doi.org/10.1371/journal.pone.0246123.g001>

- Voluntary snort (mouth-closed maximum effort nasal exhale) with no therapy, with 30LPM NHF, and with 60LPM NHF.

Chemical marker method

Ten healthy volunteers (aged 23–48, 1 female and 9 male) participated. Participants sat in a chair with a headrest. Each participant carried out the sequence of actions described in Table 1. The order of the no-therapy and 60 LPM therapy actions was randomized. Participants acclimatized to the 60 LPM therapy for a few minutes before beginning the NHF tests. Where NHF was used, an Optiflow™+ cannula (OPT946, OPT944, OPT942) was selected, and was used with an Airvo™2 humidifier set to 37°C and 100% relative humidity (44 mg/L). Immediately before each measurement, the participant instilled 0.5 mL of marker solution into each nostril. 0.5 mL was assumed sufficient as excess ran out of the nose. For coughing and sneezing, the participant placed an additional 1 mL onto their tongue, via pipette. The marker solution was 2.8 grams of riboflavin 5' monophosphate sodium salt hydrate (Sigma-Aldrich, St Louis, MO, USA, F6750-25G, fluorimetric grade, 73–76% purity) per litre of deionized water.

Air was sampled at a distance of either 100 mm or 500 mm from the participant's nose, using 125 mm diameter qualitative filter paper (Whatman plc, Little Chalfont, Bucks, UK, product number 1005–125) supported on an acrylic grille through which air was drawn at 2.2–18.1 LPM with a vacuum pump. The air flow rate was measured with a TSI 4040 meter (TSI Inc. Shoreview, MN, USA). This sampling system was placed to intercept the maximum exhaled nasal velocity, determined for each test after the participant found a position they

Table 1. Actions for chemical marker test.

Action	Therapy	repeats	Sampling distance	Duration
Quiet breathing	No therapy	2–3	1–2 at 100 mm; 1 at 500 mm	7 mins
Voluntary snort (mouth closed, expel air through nose with maximum effort)	No therapy	1	500 mm	30 sec
Voluntary cough (mouth open)	No therapy	1	500 mm	30 sec
Voluntary sneeze (allow mouth to open)	No therapy	1	500 mm	30 sec
Quiet resting breathing	60 LPM	2–3	1–2 at 100 mm; 1 at 500 mm	7 mins
Voluntary snort (mouth closed, expel air through nose with maximum effort)	60 LPM	1	500 mm	30 sec
Voluntary cough (mouth open)	60 LPM	1	500 mm	30 sec
Voluntary sneeze (allow mouth to open)	60 LPM	1	500 mm	30 sec

<https://doi.org/10.1371/journal.pone.0246123.t001>

could maintain comfortably for the duration. The filter papers were stored in Petri dishes (used as delivered in clean sterile packaging) and frozen for later analysis. A clean grille was used after each block of quiet breathing tests, and after each snort, cough or sneeze.

Background measurements (7 min duration) were run before and after each participant. No riboflavin was detected in any of these, indicating the room ventilation was adequate to prevent contamination between tests.

For quantitative analysis, the samples were brought to room temperature and riboflavin was extracted from the filter paper using 3.5 ml of Milli-Q water (Merck Millipore, Burlington, MA, USA) with 5 minutes of gentle agitation. 1.5 mL of the supernatant was drawn off and expelled through a 0.45 μm filter into HPLC vials. These were analyzed with a Dionex UHPLC Focused (Thermo Fisher Scientific, Waltham, MA, USA) fitted with an autosampler, Ultimate[®] 3000 pump, and Ultimate[®] 3000 fluorescence detector. 20 μL samples were injected into a Kinetex 5 μm C18 100 Å, 100 x 2.1 mm LC Column (Phenomenex, Torrance, CA, USA). The mobile phase was 95% NH_4HCO_3 and 5% methanol. Samples were run at a column temperature of 35°C, pressure of 62 bar and an isocratic flow rate of 0.2 mLPM for a total run time of 36 minutes.

A six-point external standard calibration curve (0, 50, 100, 200, 400, 800 and 1000 ng/mL) of 95% purity riboflavin 5' monophosphate (Sigma Aldrich, F8399) was used for the quantification of samples and the calibration standards were analyzed prior to starting the sample sequence. Milli-Q blanks were analyzed after the calibration standards and after every 14 samples to ensure there was no carry-over from the previous runs. A 100 ng/mL check standard was run after every sample sequence to confirm the validity of the calibration curve. Calibration standards and samples were analyzed in duplicate aliquots. Chromeleon (c) Dionex (Version 7.2.7.10369) software was used for peak fitting and calibration.

The concentration of oral/nasal fluid emitted by the participant and collected by the sampling system was calculated using the concentration of the riboflavin, the air flow rate through the filter paper, the duration of the test, and the volume of Milli-Q water used to extract the riboflavin.

The duplicate aliquots agreed within 4% except for two instances in which four overlapping peaks were fitted at the riboflavin retention time.

The detection limit for riboflavin, estimated based on the signal to noise ratio in the chromatogram ($S/N = 3$) was 2.75 ng/mL. The concentration of oral/nasal fluid in air required to meet this detection limit is given in Table 2.

Results

(1) Imaging. During quiet breathing with no therapy and with 30 LPM NHF, no particles were detected for any of the participants tested. Particles were detected during quiet breathing with 60 LPM NHF, for two of the six participants.

When snorting, five out of six participants produced visible particles in all conditions. An example image is shown in Fig 2. The particles ranged in diameter from the smallest detectable

Table 2. Detection limits of oral/nasal fluid.

Air flow rate (LPM)	Test duration (min)	Detection limit (μL oral/nasal fluid per m^3 air)
2.5	0.5	3.6
18.1	0.5	0.5
2.3	7	0.28
12.7	7	0.05

<https://doi.org/10.1371/journal.pone.0246123.t002>




Fig 2. Particles during snort, no therapy (left) and snort, 60 LPM NHF (right). From top to bottom on the right of each image is a silhouette of a participant's nose, lips (left image) or nasal cannula (right image) and chin.

<https://doi.org/10.1371/journal.pone.0246123.g002>

size of 33 μm to 5000 μm (5mm) in diameter. Interpersonal variation was large. One (female) participant produced no detectable particles with NHF at 60LPM.

The number of particles detected (mean, minimum and maximum), are given in Table 3 and Fig 3 as a function of size. The depth of focus limits the accuracy of the size measurement. Data are shown only for the four experimental conditions in which particles were present. The values are averaged over three repeats on each the left and right nostril. There was no significant difference between left and right nostrils so the data are combined for presentation here, as well as over the three replications.

Fig 3 shows that with quiet breathing, no particles were recorded with unsupported breathing or 30 LPM NHF (detection limit for single particles 33 μm). Particles were detected from 2 of 6 participants at 60 LPM quiet breathing at approximately 10% of the rate caused by unsupported vigorous breathing. Quiet and vigorous breathing gave very different particle numbers ($p < 0.001$). Unsupported vigorous breathing released the greatest numbers of particles. Vigorous breathing with NHF at 60 LPM released half the number of particles compared to vigorous breathing without NHF. For vigorous breathing, the type of therapy has no significant effect ($p = 0.3135$).

Table 3. Summary of average particle numbers across six participants and for the four conditions for which particles were detected by imaging.

Particle dia. (μm)	Quiet breathing, 60 LPM			Snort, no therapy			Snort, 30 LPM			Snort, 60 LPM		
	Mean	Min	Max	Mean	Min	Max	Mean	Min	Max	Mean	Min	Max
50	0.8	0.0	2.5	5.0	0.0	18.3	3.0	0.0	10.5	3.4	0.0	9.9
100	2.5	0.0	10.0	14.7	0.0	46.7	9.7	0.0	38.3	11.9	0.0	34.1
150	2.5	0.0	10.2	28.9	0.5	121.0	14.7	0.0	59.2	18.4	1.2	62.9
200	2.6	0.0	10.3	26.4	1.7	101.0	11.6	0.0	39.3	16.0	1.4	50.7
500	5.9	0.0	21.0	72.9	2.7	276.8	30.4	0.0	119.3	45.9	6.3	136.3
1000	0.6	0.0	2.7	24.0	1.0	78.8	9.6	0.0	28.5	10.2	1.7	24.6
2000	0.1	0.0	0.3	6.1	0.3	19.7	1.3	0.0	3.5	0.8	0.0	3.2
5000	0.1	0.0	0.5	0.6	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.1

<https://doi.org/10.1371/journal.pone.0246123.t003>




Fig 3. Number of particles (averaged over both nostrils and all participants). Error bars are 1 standard deviation.

<https://doi.org/10.1371/journal.pone.0246123.g003>

(2) Chemical marker. The calculated quantities of oral/nasal fluid in the air captured by the sampler are given in Table 4, together with the mean and standard deviations calculated over all participants. The data is summarized in Fig 4.

Only the obvious difference in quiet versus vigorous breathing was significant ($p < 0.001$). There were no significant differences due to therapy, nor between types of vigorous breathing, nor due to distance (quiet only), nor due to therapy order, and there were no two-way interactions between these factors.

Oral/nasal fluid was not detected in quiet resting breathing without NHF therapy. Oral/nasal fluid was detected 4 times in 29 tests in quiet breathing with NHF therapy. It never exceeded 17 μL per cubic metre of sampled air, and counting only those instances where it was

Table 4. Results of the chemical marker tests expressed as the concentration of oral/nasal fluid in air. Values for each subject are the mean of the duplicate aliquots. Zero values indicate any marker present was below the detection limit. The second quiet breathing, 100 mm distance test was omitted for Participant Four due to time limitations.

		μL oral/nasal fluid per cubic metre of air												
		Participant												
	Therapy	Dist (mm)	1	2	3	4	5	6	7	8	9	10	Mean	s.d.
Quiet	No	100	0	0	0	0	0	0	0	0	0	0	-	-
Quiet	No	100	0	0	0	Omitted	0	0	0	0	0	0	-	-
Quiet	No	500	0	0	0	0	0	0	0	0	0	0	-	-
Snort	No	500	260	2,843	27.6	11.9	145	30.5	13,786	678	2,419	259	2,046	4,252
Cough	No	500	5.13	19.4	38.7	117	24.9	0.00	4,233	1,080	10.1	804	633	1,323
Sneeze	No	500	2,507	48.3	0.00	66.2	110	132	3,445	2,379	193	10,219	1,910	3,194
Quiet	60 LPM	100	0.00	0.00	0.00	1.68	6.12	0.00	0.00	0.00	0.00	0.00	0.78	1.95
Quiet	60 LPM	100	0.00	0.00	17.0	Omitted	0.00	0.00	0.00	0.00	0.26	0.00	1.72	5.64
Quiet	60 LPM	500	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Snort	60 LPM	500	13.2	1,424	21.0	21.1	43.2	980	489	86.2	1,541	211	483	608
Cough	60 LPM	500	157	606	37.8	17.5	0.00	106	15,274	3,484	335	382	2,040	4,766
Sneeze	60 LPM	500	1,327	9.71	31.2	26.4	12.8	60.3	2,133	8,739	249	923	1,351	2,695

<https://doi.org/10.1371/journal.pone.0246123.t004>




Fig 4. Summary of data from chemical marker test. Black circles are the means, error bars are \pm one standard deviation (due to the logarithmic scale, the negative error bar is obscured by the datapoint marker), and bars show the range from minimum to maximum. White bars are no therapy (NT), grey bars are 60 LPM NHF. The figure of 100 or 500 is the distance in mm. The solid line is the maximum detection limit and the dashed line is the minimum (as detectability depends on air flow rate).

<https://doi.org/10.1371/journal.pone.0246123.g004>

detected, it was at a mean level of 6.3 μL per cubic metre of sampled air. This was 1/200 th of the average level detected in snort, cough or sneeze. It was detected in two cases during quiet breathing where this was the first action the participant did, and in two cases where they completed no-therapy actions first.

With no therapy, oral/nasal fluid was detected in quantities exceeding 633 μL per cubic metre in all snorts, nine out of ten coughs, and nine out of ten sneezes.

With NHF (60 LPM), oral/nasal fluid was detected in quantities exceeding 483 μL per cubic metre in all snorts, 9 out of 10 coughs, and all sneezes.

Snort, cough and sneeze all release the same order of magnitude of oral/nasal fluid. The quantities detected in with-therapy and no-therapy cases are of similar order of magnitude.

Discussion

To our knowledge this is the first study to compare the optical video-microscopy and chemical marker methods for oral/nasal fluid dispersion in the presence and absence of NHF. It was evident from both measurement modalities that high energy respiratory maneuvers like coughing, sneezing and snorting generated high volumes of particles, either with or without NHF, compared to quiet breathing. Higher expired flow velocities are expected to generate stronger shear forces over the mucosa, generating more airborne particles [6].

During vigorous breathing there were fewer particles produced with NHF than without NHF. This was true at both flow rates in the imaging tests, and true when averaged over snort, cough and sneeze in the marker tests. NHF's apparent mitigation of particle generation during

vigorous breathing may be explained by particles impacting on the cannula interface. Another possible explanation is that NHF imposes an expiratory flow resistance that increases expiratory time [10] and reduces the peak expiratory flow [11]. Although NHF contributes to higher nasal velocities [12], patient peak expiratory velocities are lower and particle generation reduced. There is high interpersonal variation in both datasets, with standard deviations typically twice the mean. Besides interpersonal differences in mucosa and air velocity, the air sampling does not capture the entire particle plume.

On the points on which they are directly comparable, the results of the two methods agree qualitatively that (1) quiet breathing with no therapy did not produce detectable aerosol, (2) some individuals produced aerosol during quiet breathing with 60 LPM therapy, (3) snorting usually produced aerosol, at much greater masses than quiet breathing, and (4) snorting with and without therapy produced particles at the same order of magnitude of mass, but lower mass with therapy.

For the oral/nasal fluid collection, it should be noted that with quiet breathing alone there were no detectable levels in the twenty nine measurements, while the addition of 60 LPM NHF increased this to four out of twenty nine tests with detectable volumes. However, these quiet breathing measurements were taken over a seven-minute period and produced 200 to 1000 times lower volumes of oral/nasal fluid than the higher energy respiratory maneuvers of coughing, sneezing and snorting achieved in a 30 second period. Looking at this another way, coughing with no therapy produced $633 \mu\text{L}/\text{m}^3$ in half a minute i.e. ($1,266 \mu\text{L}/\text{m}^3/\text{min}$). Quiet breathing with NHF at 60 LPM produced on average $1.72 \mu\text{L}/\text{m}^3$ in 7 minutes ($0.246 \mu\text{L}/\text{m}^3/\text{min}$). It would take 86 hours of quiet breathing with NHF at 60 LPM to release the same quantity of oral/nasal fluid as a minute of coughing with no therapy ($1,266/1.72 = 5,146$ mins or 86 hours). Cough is a common symptom for coronavirus, with a recent study reporting an average cough frequency of 17 events in a 30 min test [13].

SARS-CoV-2 RNA has been detected in particles of $0.25\text{--}4 \mu\text{m}$ diameter [14, 15]. At 7 mins sampling time, the smallest quantity of fluid that the chemical marker technique can detect is $0.28 \mu\text{L}$ per m^3 of air. For particles of $1.75 \mu\text{m}$, this detection limit is 10 particles per cm^3 . This is greater than the concentrations produced by breathing and speaking, though in breathing the particles are thought to be produced in the bronchioles [16], and the bronchiolar fluid would not carry any riboflavin marker. Further studies are needed with more sensitive techniques.

It has been postulated that a higher clinical acuity Acute Respiratory Distress Syndrome (ARDS) patient will generate more particles due to higher work of breathing, increased closing capacity and altered respiratory tract fluid [7]. In a recent study using a green laser and an iPhone camera, it was demonstrated that a healthy participant generates droplets/particles when speaking, with the number of detectable particles increasing with speech volume. The number of particles was markedly reduced when talking through a slightly damped washcloth [17]. In an ICU based study by Leung et al. [18], Petri dishes were positioned at 0.4 and 1.5 m around critically ill patients with Gram-negative bacterial pneumonia. The results suggested that there was no increase of surface or air contamination using NHF compared to conventional oxygen masks [18]. A simulation breathing manikin and smoke generation system, in conjunction with laser sheet light and high resolution imaging system was used to quantify air dispersion in some elegant research by Hui et al. [19, 20]. The simulation work demonstrated that NHF was no worse, and was arguably better, than the CPAP systems used as a comparison. A study using a manikin assessed the potential for pathogen dispersal during NHF and found detection of water and yeast only in the proximal locations, < 60 cm from the face [21].

One study had five healthy participants sit in a chair, gargle 10 ml of food coloring then cough, and measure how far the visible droplets went on paper on the floor. They reported

that the discernable particles traveled on average 2.48 m with no therapy and 2.91 m with NHF at 60 LPM [22]. While this rudimentary methodology implies NHF may have increase the dispersion distance slightly, both are further than the 2 m frequently stated as a safe distance in guidelines [5]. These findings were reinforced by a study from two hospitals in Wuhan, China that measured the dispersion distance of Coronavirus 2 in the ICU and ward environments, and found virus nucleic acid up to 4 m from the patient beds [23].

This study's findings are in general concordance with these other published studies of particle dispersion with NHF. However there is still a dearth of high quality data regarding aerosol and droplet generation, and this should be resolved to improve the understanding of the possible mechanism of transmission, and to inform evidence based guidelines for health care workers treating patients infected with Covid-19 and related diseases [5].

Many clinical interventions and therapies are considered to have the potential to generate aerosols, including standard oxygen therapy, non-invasive ventilation, intubation, nebulisation and NHF therapy. It is important to gain a full understanding of the potential benefits of using any of these therapies in the context of any associated risks. The mechanism of droplet and aerosol virus transmission is also not fully understood. The emerging evidence suggests the generation of numbers of particles increases with the vigor of the respiratory activity.

The potential benefits of using NHF therapy should be weighed against the risks. One of the primary indications for use of NHF is treating type 1 respiratory failure. In a large RCT conducted in 23 ICUs in France and Belgium involving 310 participants, NHF was reported to reduce intubation rates compared to non-rebreather face mask or NIV for a subgroup of those with Acute Hypoxic Respiratory Failure (AHRF) and a $\text{PaO}_2\text{:FIO}_2$ of 200 mm Hg or less, of whom the majority had community acquired pneumonia [1]. This study by Frat et al. [1] was one of nine RCTs synthesized in a meta-analysis comparing standard oxygen to NHF in AHRF [2]. The results of this meta-analysis suggested a reduced intubation rate and escalation of oxygen therapy [2]. It could be argued that if using NHF reduces the need for intubation, employing a pragmatic approach could improve the outcome for the patient, by reducing the use of more invasive therapies, and reduce the exposure risk to the HCW.

A systematic review of SARS-related literature conducted to understand the risk of transmission to healthcare workers from aerosol-generating procedures [3], reported that intubation was a high-risk procedure. The same review reported oxygen, high flow oxygen or BiPap mask were low risk. [24] measured particle concentration in the air near subjects wearing NHF, and found that airborne particle concentration did not significantly increase with the use of NHF during normal breathing, talking, deep breathing, or coughing. There is also some evidence that humidity may play a role in preserving the ability of the mucous membrane to resist the infection [25], modelling work that suggests increased humidity may inhibit the displacement of expelled particles [26], and that coronaviruses are humidity and temperature sensitive [25], so there is speculation the higher temperatures and humidity levels of NHF might reduce the viable virus dispersion compared to dry gas therapy. In one recent study on COVID-19 patients, NHF was reported to be the most common ventilation support, although it was used to greater success in the patients with $\text{PaO}_2\text{/FiO}_2$ ratios above 200 [27].

There is speculation that NHF may increase the chances of aerosol generation and COVID-19 transmission. However, there is a lack of evidence to support that NHF is any worse than other low risk respiratory therapy such as oxygen therapy or NIV, and its use may avoid the need for high risk procedures such as intubation.

This study had numerous limitations: the sample size is small, all participants were healthy; there was a narrow age distribution (although previous research indicates no reason to expect different results from other participant in quiet breathing. Tobin et al. [28], measured the breathing patterns of 65 healthy participants from 20 to 81 years of age and found no effect of

age on the mean values of various breathing pattern components. Populations being treated with NHF and vulnerable to respiratory infection are likely to have lower peak expiratory flow in snort, cough and sneeze). All participants were in a sitting position and a supine position may give different results; the imaging could not detect particles of less than 33 microns in diameter; the chemical marker could not discriminate on particle size, and due to the limited physical size of the filter paper, might not collect all of the discharge plume. In both methods, some of the sample fluid used to moisten the mucosa was swallowed. In both methods the instilled fluid was either saline or water and as such, be more easily atomized and/or produce smaller diameter particles. There was considerable variability in the results. It is speculated that this large variability is due to a range of factors including: some of the 1 ml sample going down the throat pre-measurement, and the variability of simulated snorting, coughing and sneezing.

Conclusions

60 LPM NHF therapy may cause some small quantity of oral/nasal fluid to be released during quiet breathing, at levels of less than 17 μ L per cubic metre of air. The addition of a filter barrier may be indicated.

Vigorous breathing (snort, cough or sneeze) releases 200 to 1000 times more oral/nasal fluid than quiet breathing.

60 LPM NHF does not make the levels of oral/nasal fluid emitted during cough, snort or sneeze greater compared to unsupported breathing.

We do not find evidence for large numbers of particles being dispersed by NHF, compared to cough or sneeze. NHF is a useful therapy for Type 1 Respiratory failure and reducing escalation to high infection risk procedures like intubation.

Vigorous breathing without NHF is the worst-case scenario that should drive infection prevention and control measures. The use of NHF, per se, does not increase the risk of generation of infectious airborne aerosols above the risk of patient-generated aerosols. Adherence to standard contact and droplet precautions are likely to be sufficient when NHF is applied.

Supporting information

S1 Data.
(XLSX)

Acknowledgments

We wish to thank Kimberly Kovacs-Wilks, Morkel Zaayman, Meike Holzenkaempfer and Amanda Inglis of the School of Physical and Chemical Sciences, University of Canterbury, for their help with the HPLC analysis.

Author Contributions

Conceptualization: M. C. Jermy, C. J. T. Spence, R. Kirton, J. F. O'Donnell, N. Kabaliuk, S. Gaw, R. L. Dougherty, P. Rowe, A. Gibbs, S. A. Roberts.

Data curation: M. C. Jermy, H. Hockey.

Formal analysis: M. C. Jermy, C. J. T. Spence, R. Kirton, J. F. O'Donnell, N. Kabaliuk, H. Hockey, Y. Jiang, P. Rowe, S. A. Roberts.

Funding acquisition: C. J. T. Spence, R. Kirton, S. A. Roberts.

Investigation: M. C. Jermy, C. J. T. Spence, R. Kirton, J. F. O'Donnell, N. Kabaliuk, P. Rowe, S. A. Roberts.

Methodology: M. C. Jermy, C. J. T. Spence, R. Kirton, J. F. O'Donnell, N. Kabaliuk, S. Gaw, Z. Zulkhairi Abidin, R. L. Dougherty, A. S. Mahaliyana, A. Gibbs, S. A. Roberts.

Project administration: M. C. Jermy, R. Kirton, S. A. Roberts.

Resources: C. J. T. Spence.

Supervision: M. C. Jermy.

Writing – original draft: M. C. Jermy, C. J. T. Spence, R. Kirton, J. F. O'Donnell, N. Kabaliuk, S. A. Roberts.

Writing – review & editing: M. C. Jermy, C. J. T. Spence, R. Kirton, J. F. O'Donnell, N. Kabaliuk, H. Hockey, S. A. Roberts.

References

1. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med*. 2015; 372(23):2185–2196. <https://doi.org/10.1056/NEJMoa1503326> PMID: 25981908
2. Rochweg B, Granton D, Wang DX, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. *Intensive Care Med*. 2019; 45(5):563–572. <https://doi.org/10.1007/s00134-019-05590-5> PMID: 30888444
3. Tran K, Cimon K, Severn M, Pessoa-Silva C, Conly J. Aerosol-generating procedures and risk of transmission of acute respiratory infections: a systematic review. *CADTH Technol Overv*. 2013; 3(1):e3201. PMID: 23463843
4. Raboud J, Shigayeva A, McGeer A, Bontovics E, Chapman M, et al. (2010) Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada. *PLoS ONE* 5(5): e10717. <https://doi.org/10.1371/journal.pone.0010717> PMID: 20502660
5. Bahl P, Doolan C, de Silva C, Chughtai AA, Bourouiba L, MacIntyre CR. Airborne or droplet precautions for health workers treating COVID-19? [published online ahead of print, 2020 Apr 16]. *J Infect Dis*. 2020;jiaa189. <https://doi.org/10.1093/infdis/jiaa189> PMID: 32301491
6. Mittal R., Ni R., & Seo J. (2020). The flow physics of COVID-19. *Journal of Fluid Mechanics*, 894, F2. <https://doi.org/10.1017/jfm.2020.330>
7. Wilson NM, Norton A, Young FP, Collins DW. Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review [published online ahead of print, 2020 Apr 20]. *Anaesthesia*. 2020; <https://doi.org/10.1111/anae.15093> PMID: 32311771
8. Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: a commentary. *BMC Infect Dis*. 2019; 19(1):101. Published 2019 Jan 31. <https://doi.org/10.1186/s12879-019-3707-y> PMID: 30704406
9. Lefebvre, A.H., "Atomization and Sprays", Taylor and Francis, 1989, ISBN 9780891166030
10. Mundel T, Feng S, Tatkov S, et al. Mechanisms of nasal high flow on ventilation during wakefulness and sleep. *J Appl Physiol* 2013 <https://doi.org/10.1152/japplphysiol.01308.2012> PMID: 23412897
11. Spence CJT, Buchmann NA, Jermy MC, et al. Stereoscopic PIV measurements of flow in the nasal cavity with high flow therapy. *Experiments in Fluids* 2010; 50:1005–1017
12. Spence CJT, Buchmann NA, Jermy MC. Unsteady flow in the nasal cavity with high flow therapy measured by stereoscopic PIV. *Experiments in Fluids* 2012; 52:569–579
13. Leung N.H.L., Chu D.K.W., Shiu E.Y.C. et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nat Med* 26, 676–680 (2020). <https://doi.org/10.1038/s41591-020-0843-2> PMID: 32371934
14. Liu Y., Ning Z., Chen Y. et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* 582, 557–560 (2020). <https://doi.org/10.1038/s41586-020-2271-3> PMID: 32340022
15. Chia P.Y., Coleman K.K., Tan Y.K. et al. Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients. *Nat Commun* 11, 2800 (2020). <https://doi.org/10.1038/s41467-020-16670-2> PMID: 32472043

16. Johnson GR, Morawska L, Ristovski ZD, Hargreaves M, Mengersen K, Chao CYH, et al. Modality of human expired aerosol size distributions, *Journal of Aerosol Science*, Volume 42, Issue 12, 2011, 839–851 <https://doi.org/https%3A/doi.org/10.1016/j.jaerosci.2011.07.009>
17. Anfinrud P, Stadnytskyi V, Bax CE, Bax A. Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering [published online ahead of print, 2020 Apr 15]. *N Engl J Med*. 2020; NEJMc2007800. <https://doi.org/10.1056/NEJMc2007800> PMID: 32294341
18. Leung CCH, Joynt GM, Gomersall CD, et al. Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. *J Hosp Infect*. 2019; 101(1):84–87. <https://doi.org/10.1016/j.jhin.2018.10.007> PMID: 30336170
19. Hui DS, Chan MT, Chow B. Aerosol dispersion during various respiratory therapies: a risk assessment model of nosocomial infection to health care workers. *Hong Kong Med J*. 2014; 20 Suppl 4:9–13. PMID: 25224111
20. Hui DS, Chow BK, Lo T, et al. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. *Eur Respir J*. 2019; 53(4):1802339. Published 2019 Apr 11. <https://doi.org/10.1183/13993003.02339-2018> PMID: 30705129
21. Kotoda M, Hishiyama S, Mitsui K, et al. Assessment of the potential for pathogen dispersal during high-flow nasal therapy. *J Hosp Infect*. 2020; 104(4):534–537. <https://doi.org/10.1016/j.jhin.2019.11.010> PMID: 31759093
22. Loh NW, Tan Y, Taculod J, et al. The impact of high-flow nasal cannula (HFNC) on coughing distance: implications on its use during the novel coronavirus disease outbreak [published online ahead of print, 2020 Mar 18]. *Can J Anaesth*. 2020;1–2. <https://doi.org/10.1007/s12630-020-01634-3> PMID: 32189218
23. Guo ZD, Wang ZY, Zhang SF, et al. Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020 [published online ahead of print, 2020 Apr 10]. *Emerg Infect Dis*. 2020; 26(7): <https://doi.org/10.3201/eid2607.200885> PMID: 32275497
24. Gaeckle NT, Lee J, Park Y, Kreykes G, Evans MD and Hogan CJ, Aerosol Generation from the Respiratory Tract with Various Modes of Oxygen Delivery, *Am J Respir Crit Care Med* Vol 202, Iss 8, pp 1115–1124, Oct 15, 2020 <https://doi.org/10.1164/rccm.202006-2309OC> PMID: 32822208
25. Lauc G, Markotić A, Gornik I, Primorac D. Fighting COVID-19 with water. *J Glob Health*. 2020; 10(1):010344. <https://doi.org/10.7189/jogh.10.010344> PMID: 32373322
26. Xie X, Li Y, Chwang AT, Ho PL, Seto WH. How far droplets can move in indoor environments—revisiting the Wells evaporation-falling curve. *Indoor Air*. 2007; 17(3):211–225. <https://doi.org/10.1111/j.1600-0668.2007.00469.x> PMID: 17542834
27. Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. *Ann Intensive Care*. 2020; 10(1):37. Published 2020 Mar 30. <https://doi.org/10.1186/s13613-020-00653-z> PMID: 32232685
28. Tobin MJ, Chadha TS, Jenouri Birch, Gazeroglu Sackner, “Breathing patterns 1. Normal Subjects” *Chest* 1983; 84(2):202–205. <https://doi.org/10.1378/chest.84.2.202> PMID: 6872603

Assessment of dispersion of airborne particles of oral/nasal fluid by high flow nasal cannula therapy

Jermy, MC

2021-02-12

<http://hdl.handle.net/10179/16292>

22/04/2023 - Downloaded from MASSEY RESEARCH ONLINE